The Effect of Dapagliflozin on Rate of Kidney Function Decline in Patients with CKD: A Prespecified Analysis from the DAPA-CKD Trial

被引：0
|
作者：
Heerspink, Hiddo J. L. [1 ,2 ]
Jongs, Niels [1 ]
Chertow, Glenn M. [3 ]
Langkilde, Anna Maria [4 ]
McMurray, John [5 ]
Correa-Rotter, Ricardo [6 ]
Rossing, Peter [7 ,8 ]
Sjostrom, David [4 ]
Stefansson, Bergur V. [4 ]
Toto, Robert D. [9 ]
Wheeler, David C. [10 ]
Greene, Tom [11 ]
机构：
[1] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands
[2] George Inst Global Hlth, Newtown, NSW, Australia
[3] Stanford Univ, Sch Med, Stanford, CA USA
[4] AstraZeneca, Gothenburg, Sweden
[5] Univ Glasgow, Glasgow, Lanark, Scotland
[6] Natl Med Sci & Nutr Inst Salvador Zubiran, Mexico City, DF, Mexico
[7] Steno Diabet Ctr Copenhagen, Gentofte, Denmark
[8] Univ Copenhagen, Copenhagen, Denmark
[9] UT Southwestern Med Ctr, Dallas, TX USA
[10] UCL, London, England
[11] Univ Utah Hlth, Salt Lake City, UT USA
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2021年 / 32卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
FR-OR51
引用
收藏
页码：35 / 36
页数：2
相关论文
共 50 条
  • [1] Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
    Heerspink, Hiddo J. L.
    Jongs, Niels
    Chertow, Glenn M.
    Langkilde, Anna Maria
    McMurray, John J., V
    Correa-Rotter, Ricardo
    Rossing, Peter
    Sjostrom, C. David
    Stefansson, Bergur, V
    Toto, Robert D.
    Wheeler, David C.
    Greene, Tom
    LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (11): : 743 - 754
  • [2] Dapagliflozin Effect on Hospital Admissions in Patients With CKD: A Post Hoc Analysis of the DAPA-CKD Trial
    Schechter, Meir
    Jongs, Niels
    Chertow, Glenn
    Mosenzon, Ofri
    McMurray, John
    Correa-Rotter, Ricardo
    Rossing, Peter
    Langkilde, Anna Maria
    Sjostrom, David
    Toto, Robert D.
    Wheeler, David C.
    Heerspink, Hiddo J. L.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 25 - 25
  • [3] Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
    Persson, Frederik
    Rossing, Peter
    Vart, Priya
    Chertow, Glenn M.
    Hou, Fan Fan
    Jongs, Niels
    McMurray, John J., V
    Correa-Rotter, Ricardo
    Bajaj, Harpreet S.
    Stefansson, Bergur, V
    Toto, Robert D.
    Langkilde, Anna Maria
    Wheeler, David C.
    Heerspink, Hiddo J. L.
    DIABETES CARE, 2021, 44 (08) : 1894 - 1897
  • [4] Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial (vol 9, pg 743, 2021)
    Heerspink, H. J. L.
    Jongs, N.
    Chertow, G. M.
    LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (10): : E10 - E10
  • [5] Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis from the DAPA-CKD Study
    Persson, Frederik
    Rossing, Peter
    Jongs, Niels
    Chertow, Glenn M.
    Hou, Fan Fan
    Vart, Priya
    McMurray, John J.
    Correa-Rotter, Ricardo
    Stefansson, Bergur
    Toto, Robert D.
    Langkilde, Anna Maria
    Wheeler, David C.
    Heerspink, Hiddo L.
    DIABETES, 2022, 71
  • [6] Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study
    Beernink, Jelle M.
    Persson, Frederik
    Jongs, Niels
    Laverman, Gozewijn D.
    Chertow, Glenn M.
    McMurray, John J. V.
    Langkilde, Anna Maria
    Correa-Rotter, Ricardo
    Rossing, Peter
    Sjostrom, C. David
    Toto, Robert D.
    Wheeler, David C.
    Heerspink, Hiddo J. L.
    DIABETES CARE, 2023, 46 (03) : 602 - 607
  • [7] Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
    Jongs, Niels
    Greene, Tom
    Chertow, Glenn M.
    McMurray, John J., V
    Langkilde, Anna Maria
    Correa-Rotter, Ricardo
    Rossing, Peter
    Sjostrom, C. David
    Stefansson, Bergur, V
    Toto, Robert D.
    Wheeler, David C.
    Heerspink, Hiddo J. L.
    LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (11): : 755 - 766
  • [8] Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial
    Wheeler, David C.
    Jongs, Niels
    Stefansson, Bergur, V
    Chertow, Glenn M.
    Greene, Tom
    Hou, Fan Fan
    Langkilde, Anna Maria
    McMurray, John J., V
    Rossing, Peter
    Nowicki, Michal
    Wittmann, Istvan
    Correa-Rotter, Ricardo
    Sjostrom, C. David
    Toto, Robert D.
    Heerspink, Hiddo J. L.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 (09) : 1647 - 1656
  • [9] Consistent Benefits of Dapagliflozin on Kidney End Points Defined by Different eGFR Thresholds: A Prespecified Analysis From DAPA-CKD
    Jongs, Niels
    Chertow, Glenn
    McMurray, John
    Correa-Rotter, Ricardo
    Rossing, Peter
    Langkilde, Anna Maria
    Sjostrom, David
    Toto, Robert D.
    Wheeler, David C.
    Heerspink, Hiddo J. L.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 848 - 848
  • [10] Effects of Dapagliflozin in Patients Without Diabetes and Microalbuminuria: An Exploratory Analysis From the DAPA-CKD Trial
    Heerspink, Hiddo J. L.
    Chertow, Glenn
    Jongs, Niels
    Correa-Rotter, Ricardo
    Rossing, Peter
    Sjostrom, David
    Langkilde, Anna Maria
    Wheeler, David C.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 847 - 848
12345